Curtis Chong, MD, PhD

About Me

I am a medical oncologist who specializes in caring for people with gastrointestinal cancers, lung cancer, and melanoma. I lead the phase I and immunotherapy clinical trials program for Memorial Sloan Kettering in New Jersey, where our team prides itself on working relentlessly to find a clinical trial for every patient referred to us. I also see patients in the early drug development and immunotherapy clinics in Manhattan.

When someone receives a cancer diagnosis, they often feel overwhelmed. I have been in this position with several of my family members. As an oncologist, my mission is to help patients and families pursue the best treatments available while still finding happiness and meaning in their lives.

When I’m not working, I enjoy traveling and long-distance running. I have completed 105 marathons in all 50 states, on six continents, and in 17 countries. I encourage my patients to make the most of every day and to incorporate exercise and physical activity into their treatment plan.

  • Clinical Expertise: Gastrointestinal Cancers; Lung Cancer; Melanoma
  • Awards and Honors: Bial Award Diploma of Distinction, Bial Foundation for Medical Research and Portuguese Republic (2011); Young Investigator Award, American Society for Clinical Oncology (2012); American Cancer Society Post-doctoral Fellowship (2014-2016); Uniting Against Lung Cancer Fellowship (2014-2016); Fellow, American College of Physicians (2014); Four-time Kaiser Permanente San Rafael Star Doctor Award (2016-2017)
  • Languages Spoken: English
  • Education: M.Phil, The University of Cambridge; MD, PhD, The Johns Hopkins University School of Medicine
  • Residencies: Massachusetts General Hospital/Harvard Medical School
  • Fellowships: Dana-Farber Cancer Institute/Harvard Medical School
  • Board Certifications: Internal Medicine; Medical Oncology


Kiefer, M. M. and Chong, C. R., eds. Pocket Primary Care. Philadelphia: Lippincott, Williams, and Wilkins. March 2014. Hematology/oncology subsection editor. Authored chapters on Routine Visit, Evidence-based Medicine, Delivering Bad News, Hypertension, Influenza/Upper Respiratory Tract Infection, Back Pain, and Alcohol Use Disorder.

Chong C. R., Bahcall M, Capelletti M, Kosaka T, Ercan D, Sim T, Sholl LM, Nishino M, Johnson BE, Gray NS, Jänne PA. “Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.” Clinical Cancer Research. 2017. 23:204-213. 

Nishino, M., Chambers, E. S., Chong, C. R., Ramaiya, N. H., Gray, S. W., Marcoux, J. P., Habatu, H., Jänne, P. A., Hodi, F. S., and Awad, M. M. “Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. ” Cancer Immunology Research. 2016. 4: 289-293. 

Chong, C. R., Wirth, L. J., Nishino, M., Chen, A. B., Sholl, L. M., Kulke, M. F., McNamee, C. J., Jänne, P. A., and Johnson, B. E. “Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors.” Lung Cancer. 2014, 86: 241-246. 

Visit PubMed for a full listing of Curtis Chong’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Clinical Trials

Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more Arrow rightAn icon showing an arrow pointing to the right.